NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Inotuzumab Ozogamicin

Last Revision: July 20, 2020.

Estimated reading time: 1 minute

CASRN: 635715-01-4

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of inotuzumab oxogamicin during breastfeeding. Because inotuzumab oxogamicin is a large protein molecule with a molecular weight of 168,000 Da and its active metabolite is 97% plasma protein bound, the amount in milk is likely to be very low. However, the half-life of inotuzumab oxogamicin is about 12.3 days and it might accumulate in the infant. Until more data become available, inotuzumab oxogamicin should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during inotuzumab oxogamicin therapy for at least 2 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Inotuzumab Ozogamicin

CAS Registry Number

635715-01-4

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Antineoplastic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Similar articles in PubMed

  • Review Obinutuzumab[Drugs and Lactation Database (...]
    Review Obinutuzumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Nivolumab[Drugs and Lactation Database (...]
    Review Nivolumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dinutuximab[Drugs and Lactation Database (...]
    Review Dinutuximab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Pertuzumab[Drugs and Lactation Database (...]
    Review Pertuzumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Cetuximab[Drugs and Lactation Database (...]
    Review Cetuximab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...